{"id":"NCT02296138","sponsor":"Boehringer Ingelheim","briefTitle":"Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.","officialTitle":"A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-13","primaryCompletion":"2017-03-08","completion":"2017-03-29","firstPosted":"2014-11-20","resultsPosted":"2018-06-04","lastUpdate":"2018-06-04"},"enrollment":7903,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]}],"arms":[{"label":"tiotropium + olodaterol high dose","type":"EXPERIMENTAL"},{"label":"tiotropium","type":"ACTIVE_COMPARATOR"}],"summary":"The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.","primaryOutcome":{"measure":"Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period.","timeFrame":"From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days","effectByArm":[{"arm":"Tiotropium 5 Microgram (μg)","deltaMin":0.97,"sd":null},{"arm":"Tiotropium (5 μg) + Olodaterol (5 μg)","deltaMin":0.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0498"},{"comp":"OG000 vs OG001","p":"0.0010"},{"comp":"OG000 vs OG001","p":"0.0080"},{"comp":"OG000 vs OG001","p":"0.0011"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":818,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Colombia","Croatia","Czechia","Denmark","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","India","Ireland","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Norway","Philippines","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["32943047","32776202","30261995","29605624"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":862,"n":3941},"commonTop":["Chronic obstructive pulmonary disease","Viral upper respiratory tract infection","Dyspnoea"]}}